Equillium, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, disclosed in a quarterly filing with the US Securities and Exchange Commission on May 13, 2020, that the antibody sequence for two substances used in the company’s tests is derived from Cuban-origin intellectual property. In the belief that the antibody sequence thus constitutes a “pharmaceutical of Cuban origin,” the company relies on the general licenses at section 515.547(b) and (c) of the Cuban Assets Control Regulations (CACR). According to the filing, Equillium submitted a request for interpretive guidance to the Office of Foreign Assets Control in order to confirm the applicability of the general license, or in the alternative, to obtain a specific license from OFAC, requesting at the same time that OFAC treat the company’s request as a voluntary disclosure, should the agency determine that the general license does not apply. In November 2019, OFAC notified Equillium of its determination that the antibody sequence does fall within the definition of “Cuban-origin pharmaceutical,” and as such falls within the ambit of the general license, allowing the company to proceed with clinical trials without further authorization from OFAC.
May 13, 2020
California company probes applicability of CACR general license
Related by Topic
New Post
European Union introduces new sanctions framework aimed at hybrid threats by Russia
October 9, 2024
News Alert
New Post
United States targets Iranian nationals who attempted to interfere in 2024 and 2020 presidential elections
October 3, 2024
News Alert
New Post
U.S., UK, and the UN sanction a former Haitian legislator and a Haitian gang leader for human rights abuse
October 2, 2024
News Alert